NEO vs. CNXC, CARG, DLO, FA, PAGS, ATHM, ALIT, CLVT, ACVA, and DXC
Should you be buying NeoGenomics stock or one of its competitors? The main competitors of NeoGenomics include Concentrix (CNXC), CarGurus (CARG), DLocal (DLO), First Advantage (FA), PagSeguro Digital (PAGS), Autohome (ATHM), Alight (ALIT), Clarivate (CLVT), ACV Auctions (ACVA), and DXC Technology (DXC). These companies are all part of the "business services" industry.
NeoGenomics vs. Its Competitors
Concentrix (NASDAQ:CNXC) and NeoGenomics (NASDAQ:NEO) are both business services companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, community ranking, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.
Concentrix has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500. Comparatively, NeoGenomics has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500.
90.3% of Concentrix shares are held by institutional investors. Comparatively, 98.5% of NeoGenomics shares are held by institutional investors. 3.2% of Concentrix shares are held by company insiders. Comparatively, 2.4% of NeoGenomics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Concentrix has a net margin of 2.61% compared to NeoGenomics' net margin of -11.92%. Concentrix's return on equity of 16.67% beat NeoGenomics' return on equity.
NeoGenomics received 484 more outperform votes than Concentrix when rated by MarketBeat users. Likewise, 70.25% of users gave NeoGenomics an outperform vote while only 54.17% of users gave Concentrix an outperform vote.
Concentrix currently has a consensus price target of $67.25, indicating a potential upside of 19.41%. NeoGenomics has a consensus price target of $13.83, indicating a potential upside of 77.35%. Given NeoGenomics' higher probable upside, analysts clearly believe NeoGenomics is more favorable than Concentrix.
Concentrix has higher revenue and earnings than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than Concentrix, indicating that it is currently the more affordable of the two stocks.
In the previous week, Concentrix had 8 more articles in the media than NeoGenomics. MarketBeat recorded 10 mentions for Concentrix and 2 mentions for NeoGenomics. Concentrix's average media sentiment score of 1.45 beat NeoGenomics' score of 0.47 indicating that Concentrix is being referred to more favorably in the media.
Summary
Concentrix beats NeoGenomics on 12 of the 19 factors compared between the two stocks.
Get NeoGenomics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NEO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeoGenomics Competitors List
Related Companies and Tools
This page (NASDAQ:NEO) was last updated on 6/11/2025 by MarketBeat.com Staff
Buy NEO Stock Free NEO Stock Alerts